Regulatory requirements in the development of advanced therapy products (cell-, gene therapy, tissue engineering products)

Regulatory authorities are active to ensure a good regulatory environment for somatic cell therapy-, gene therapy- and tissue engineering products (in the EU known as ‘Advanced Therapy Medicinal Products’). Both the EMEA and the FDA have, amongst others, issued guidelines to address the specific aspects of these products